Menu
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals.
In the context of the current opioid crisis, we aim to become the key player of reference in the pain field, through the design and proposition of new active pharmaceutical ingredients based on the development of first-in-class polypetides derived from TAFA4 and its constituent peptides. At Tafalgie Therapeutics, we aim to develop more effective, better-tolerated, non-addictive, long-term treatments to relieve acute pain, whether mild, moderate or severe, and to prevent chronic pain, and to delivery these treatments to patients. In the medium term, we aim to form partnership agreements with major pharmaceutical companies or specialist international distributors capable of bringing products based on TAFA4 technology to the market.
Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein that modulates the transmission of pain information to the brain.
Tafalgie Therapeutics has developed and identified other new drug candidates.
surgical interventions are performed annually
undergoing surgery experience pain.
people in Europe suffer from chronic pain.
do not receive appropriate treatment for their pain.
Specialist of the peripheral nervous system
Publication in International Journal
Investor Biotech Entrepreneur
Successful IPOs
25 years experience
Chemical Industry
Strategic positions in Marketing
Scale up
Pain research
Mice Models Characterization
Production
Professor of clinical pharmacology (AMU)
Past positions : Regulatory Industrial
Tafalgie Therapeutics is a member of two French networks dedicated to healthcare innovation. Discovered :
“Pain is considered to be the root cause of almost two thirds of medical consultations. For this reason, it is the subject of many studies, both fundamental and clinical. Active research on this subject IS absolutely essential to improve our understanding of the mechanisms involved in pain and for the development of new treatments.”
Site Inserm
Aziz Moqrich explains to Thierry Lhermitte (France Inter) how pain is modulated in the human body.
Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals.